As drugs that target the BCR are not classic cytotoxic agents, their ability to inhibit their downstream targets and disrupt chemokine/cytokine interactions, which are essential for CLL cell homing and survival, are critical to their mechanism of action. Here, BCR is linked to B-cell chronic lymphocytic leukemia.